Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical firm NewLink Genetics has entered into an exclusive worldwide license agreement with Genentech, a member of the Roche, to develop its IDO pathway inhibitor NLG919.
Subscribe to our email newsletter
The two firms have also entered into a research collaboration for the discovery of next generation IDO/TDO compounds.
As part of the deal, NewLink will receive $150m in upfront payment and will also be eligible to receive in excess of $1bn in milestone payments based on achievement of certain predetermined milestones as well as escalating double-digit royalties on potential commercial sales of multiple products by Genentech.
The deal will see Genentech fund future research, development, manufacturing and commercialization costs.
The company will also provide research funding to NewLink for support of the research collaboration, while NewLink will continue to pursue development activities related to NLG919 in combination with its new HyperAcute vaccine platform.
In the US, NewLink will retain the option for co-promotion rights for NLG919 and potential next generation IDO/TDO compounds.
NewLink chairman and chief executive officer Charles Link said the alliance allows the company to accelerate and expand development of NLG919 while it continues to advance its other promising clinical and preclinical development programs.
"Genentech’s oncology development expertise, commercial leadership and history of successful strategic alliances make it an ideal collaborator to bring the potential benefits of NLG919 to patients," Link said.